Participated · Equity · Jun 2024

Insightec develops and commercializes the Exablate Prime focused-ultrasound platform to provide incisionless, immediate tremor treatment for patients with medication-refractory essential tremor and Parkinson’s disease. The Exablate Prime platform is FDA approved for those indications. The company reports over 160 systems installed worldwide and its technology has been used in nearly 20,000 commercial applications. Led by CEO Maurice R Ferré, Insightec is based in Haifa, Israel and Miami, FL, and also has offices in Dallas, Shanghai, and Tokyo. The company raised $150M in equity financing and intends to use the funds to expand operations and advance its development efforts. Insightec develops and commercializes the Exablate Neuro platform, which uses MRI‑guided acoustic energy to deliver incisionless neurosurgery for medication‑refractory Essential Tremor and Parkinson’s Disease. The company is led by CEO Maurice R. Ferré and is conducting research and clinical trials to expand applications into neuro‑oncology and other neurological conditions in partnership with academic and medical institutions. Insightec intends to drive broader adoption of its incisionless treatments while continuing to advance innovation and clinical research. Financially, the company signed a credit facility for up to $200 million with affiliates of existing shareholders Perceptive Advisors and Community Fund, receiving $100 million at closing. The facility is interest‑only for five years and matures on August 31, 2027, with an additional $100 million potentially available in tranches through 2024. The company operates from Haifa, Israel and Miami, Florida, and has additional offices in Dallas, Shanghai, and Tokyo. Insightec makes a magnetic resonance–guided focused ultrasound device that ablates the thalamus using high‑intensity sound waves to reduce hand tremors without an incision. The device is approved by the FDA to treat essential tremor in patients unresponsive to medication and has expanded approval for tremor‑dominant Parkinson’s disease. The procedure is unilateral and currently can be performed on only one side of the brain, typically addressing the dominant hand. The company has redirected focus toward neurology after earlier work on other indications, such as uterine fibroids, saw limited hospital traction. Insightec has sold its technology to more than 65 health systems worldwide, and a study of 76 essential tremor patients funded in part by the company reported 58% of patients had at least a 50% improvement in hand tremor and function at three years. Its global headquarters is in Israel and its U.S. headquarters is in Miami. Insightec is a commercial-stage medical device company that develops MRI-guided focused ultrasound platforms for non-invasive surgical therapies. Its therapy platforms, Exablate and Exablate Neuro, are proven technologies with clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. Led by Maurice R. Ferré, MD, CEO and Chairman of the Board, the company brings solutions to patients by collaborating with physicians, medical institutions, academic researchers and regulatory bodies worldwide. Insightec is based in Haifa, Israel, and Miami, Florida, and also maintains offices in Dallas, Tokyo and Shanghai. The company intends to use new funds to further commercialize its approved indications and to continue research into Parkinson’s disease, Alzheimer’s disease and brain tumors. It recently raised $150M in a Series E pre-IPO financing. Insightec develops a non-invasive therapy platform based on Magnetic Resonance-guided Focused Ultrasound (MRgFUS). Founded in 1999 and based in Dallas, Texas and Haifa, Israel, the company’s technology is already used by physicians in more than 120 medical facilities worldwide. Its indications are expanding across neurosurgery, oncology and gynecology. The company is privately held by GE Healthcare, Elbit Imaging, York Capital Management, GEOC Hengtong Investment Limited Partnership and MediTech Advisors. Insightec recently secured $22M in a Series D financing. Leadership will transition to newly appointed CEO Dr. Maurice R. Ferré, while founder and former CEO Dr. Kobi Vortman will move to the board and continue to drive strategy and the product roadmap.

Led · Series B · May 2012

Ziften provides continuous endpoint visibility to enterprises, combining real-time user, device and threat behavior monitoring, analytics, and reporting. Its solution is architected for rapid deployment—hours, not days—and for ultra-low resource consumption so it can scale dynamically across organizations. Ziften’s product is designed to discover, analyze, and respond to security exposures to harden corporate resiliency and augment existing security tools and teams. The company positions itself as a leader in endpoint threat detection and visibility and cites rapid adoption and industry recognition. This funding round is intended to accelerate its go-to-market strategy and extend its global reach. Ziften highlights recent awards and inclusion on vendor lists as signs of market traction. Ziften Technologies builds BLISS (Behavioral Lightweight Intelligence for Stressed Systems), a Desktop Quality of Service (QoS) product that monitors resource consumption and dynamically prioritizes processes across physical and virtual Windows desktops. BLISS uses lightweight behavioral algorithms, classification, and machine learning to make near-zero-administration decisions that improve uptime, performance, security, and reduce errors and annoyances. Ziften says it brings expertise from antivirus and hardware industries and has experience deploying behavioral software to more than 150 million systems worldwide. The company plans to expand its core technologies and bring BLISS to a wider audience of enterprise customers. Early deployments at multiple Fortune 500 customers reportedly improved application performance, uptime on older PCs, and employee productivity. Financially, Ziften has raised $11.3 million to date, including a newly announced $5.5M Series B. Ziften was founded in 2010 and is based in Austin, Texas. Ziften Technologies provides enterprise software designed to help organizations understand and control what applications run across Windows desktop environments. Its platform enables organizations to automatically eliminate, restrict, or accelerate applications based on relative business value. The company was launched and is led by founder and CEO Mark Obrecht, who previously founded WholeSecurity (acquired by Symantec in 2005). Ziften’s team includes experts who previously led product innovations at WholeSecurity, Intel, Cisco, Dell, Akamai, Symantec, AMD and Caltech. The company closed a $5.8M Series A to support its early commercial and product efforts.